These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 19584163)

  • 21. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
    Attard G; Clark J; Ambroisine L; Fisher G; Kovacs G; Flohr P; Berney D; Foster CS; Fletcher A; Gerald WL; Moller H; Reuter V; De Bono JS; Scardino P; Cuzick J; Cooper CS;
    Oncogene; 2008 Jan; 27(3):253-63. PubMed ID: 17637754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
    Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
    Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
    Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R
    BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
    de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
    Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
    Barry M; Perner S; Demichelis F; Rubin MA
    Urology; 2007 Oct; 70(4):630-3. PubMed ID: 17991527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 32. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
    Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
    Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
    Gopalan A; Leversha MA; Satagopan JM; Zhou Q; Al-Ahmadie HA; Fine SW; Eastham JA; Scardino PT; Scher HI; Tickoo SK; Reuter VE; Gerald WL
    Cancer Res; 2009 Feb; 69(4):1400-6. PubMed ID: 19190343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
    Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
    Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
    Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
    Blackburn J; Vecchiarelli S; Heyer EE; Patrick SM; Lyons RJ; Jaratlerdsiri W; van Zyl S; Bornman MSR; Mercer TR; Hayes VM
    Prostate; 2019 Jul; 79(10):1191-1196. PubMed ID: 31090091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.